Valeo Chalks Up Another Milestone For Canadian Enoxaparin Biosimilars
Follows Backing To Be Listed On The Quebec Public Health Plan
Executive Summary
Canada’s Valeo Pharma insists it has “worked tirelessly to ensure a robust supply of Redesca,” after completing another milestone for the company’s enoxaparin biosimilar product.